Astex Pharmaceuticals Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, presented the final results of a Phase 2 study of SGI-110, a novel hypomethylating agent in elderly Acute Myeloid Leukemia (AML) in an oral session on June 14 at the European Hematology Association meeting held in Milan, Italy (June 12-15).

Help employers find you! Check out all the jobs and post your resume.

Back to news